# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ASSAY ONLY

I Background Information:

A 510(k) Number K200210   
B Applicant Siemens Healthcare Diagnostics, Inc.   
C Proprietary and Established Names ADVIA Centaur $\textsuperscript { \textregistered }$ Total hCG assay   
D Regulatory Information

<table><tr><td rowspan=1 colspan=1>ProductCode(s)</td><td rowspan=1 colspan=1>Classification</td><td rowspan=1 colspan=1>RegulationSection</td><td rowspan=1 colspan=1>Panel</td></tr><tr><td rowspan=1 colspan=1>DHA</td><td rowspan=1 colspan=1>Class II</td><td rowspan=1 colspan=1>21 CFR 862.1155 - Human ChorionicGonadotropin (HCG) Test System</td><td rowspan=1 colspan=1>CH - ClinicalChemistry</td></tr></table>

# II Submission/Device Overview:

A Purpose for Submission: New Device   
B Measurand: Human chorionic gonadotropin (hCG)   
C Type of Test: Quantitative, chemiluminescent immunoassay

# III Intended Use/Indications for Use:

A Intended Use(s):

See Indications for Use below.

# B Indication(s) for Use:

For in vitro diagnostic use in the quantitative determination of human chorionic gonadotropin (hCG) in serum or plasma (EDTA or lithium heparin) using the ADVIA Centaur $\textsuperscript { \textregistered }$ XP system.

Human chorionic gonadotropin measurements are intended for use as an aid in the early detection of pregnancy.

C Special Conditions for Use Statement(s):

Rx - For Prescription Use Only

D Special Instrument Requirements:

ADVIA Centaur XP System.

# IV Device/System Characteristics:

# A Device Description:

The ADVIA Centaur $\textsuperscript { \textregistered }$ Total hCG assay reagents come in two configurations containing either one or five ReadyPack primary reagent pack and ADVIA Centaur Total hCG Master Curve card.

The ReadyPack consists of the following:

ADVIA Centaur ThCG ReadyPack $\textsuperscript { \textregistered }$ primary reagent pack; Lite Reagent $5 . 0 \mathrm { m L }$ /reagent pack polyclonal goat anti-hCG antibody $( \mathrm { { \sim } 0 . 1 \ \mu \mathrm { { g / m L } } } )$ labeled with acridinium ester in buffered saline with sodium azide $( 0 . 1 \% )$ and preservatives

ADVIA Centaur ThCG ReadyPack primary reagent pack; Solid Phase Reagent $2 2 . 5 \mathrm { m L }$ reagent pack monoclonal mouse anti-hCG antibody $( { \sim } 0 . 0 2 \ \mathrm { m g / m L } )$ covalently coupled to paramagnetic particles in buffered saline with sodium azide $( 0 . 1 \% )$ and preservatives

ADVIA Centaur ThCG ReadyPack ancillary reagent pack; ThCG Diluent $2 5 . 0 \mathrm { m L } /$ reagent pack buffered heat-treated equine serum with EDTA, sodium azide $( < 0 . 1 \% )$ , and preservatives

ADVIA Centaur ThCG Diluent $5 0 . 0 \mathrm { m L } / $ vial buffered heat-treated equine serum with EDTA, sodium azide $( < 0 . 1 \% )$ , and preservatives

# B Principle of Operation:

The ADVIA Centaur $\textsuperscript { \textregistered }$ Total hCG (ThCG) assay uses constant amounts of two antibodies. The first antibody, in the Lite Reagent, is a polyclonal goat anti-hCG antibody. The second antibody, in the Solid Phase, is a purified monoclonal mouse anti-hCG antibody. These two antibodies are specific for different epitopes that are present on both the free ß-subunit and the ß-subunit of intact hCG.

# V Substantial Equivalence Information:

A Predicate Device Name(s): Atellica IM Total hCG (ThCG)

B Predicate 510(k) Number(s): K172322

C Comparison with Predicate(s):

<table><tr><td colspan="1" rowspan="1">Device &amp; PredicateDevice(s):</td><td colspan="1" rowspan="1">K200210</td><td colspan="1" rowspan="1">K172322</td></tr><tr><td colspan="1" rowspan="1">Device Trade Name</td><td colspan="1" rowspan="1">ADVIA Centaur® TotalhCG assay</td><td colspan="1" rowspan="1">Atellica IM Total hCG (ThCG)assay</td></tr><tr><td colspan="1" rowspan="1">General DeviceCharacteristicSimilarities</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">IntendedUse/Indications For Use</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">For in vitro diagnostic use in thequantitative determination ofhuman chorionic gonadotropin(hCG) in human serum orplasma (EDTA or lithiumheparin) as an aid in the earlydetection of pregnancy.</td></tr><tr><td colspan="1" rowspan="1">Measurement</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">Quantitative</td></tr><tr><td colspan="1" rowspan="1">Assay Principle</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">2-site Sandwich immunoassay</td></tr><tr><td colspan="1" rowspan="1">Technology</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">Direct chemiluminescent</td></tr><tr><td colspan="1" rowspan="1">Sample Type</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">Serum, EDTA Plasma, lithiumheparin plasma</td></tr><tr><td colspan="1" rowspan="1">Calibration</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">2-point</td></tr><tr><td colspan="1" rowspan="1">General DeviceCharacteristicDifferences</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Assay Range</td><td colspan="1" rowspan="1">4.0-1000 mIU/mL (IU/L)</td><td colspan="1" rowspan="1">2.6-1000 mIU/mL (IU/L)</td></tr><tr><td colspan="1" rowspan="1">Sample Volume</td><td colspan="1" rowspan="1">50 μL</td><td colspan="1" rowspan="1">25 μL</td></tr><tr><td colspan="1" rowspan="1">Reagent Volume</td><td colspan="1" rowspan="1">100 μL of Lite Reagentand 450 μL of Solid Phase</td><td colspan="1" rowspan="1">50 µL of Lite Reagent and 255μL of Solid Phase</td></tr><tr><td colspan="1" rowspan="1">Incubation Time</td><td colspan="1" rowspan="1">7.5 minutes at 37°C.</td><td colspan="1" rowspan="1">8 minutes at 37°C.</td></tr><tr><td colspan="1" rowspan="1">Traceability</td><td colspan="1" rowspan="1">The ADVIA Centaur TotalhCG assay is traceable tothe World HealthOrganization (WHO) 5thIS 7/364 referencematerial.</td><td colspan="1" rowspan="1">The Atellica IM ThCG assaystandardization is traceable tothe World Health Organization(WHO) 4th IS 75/589 referencematerial. Assigned values forcalibrators are traceable to thisstandardization.</td></tr></table>

# VI Standards/Guidance Documents Referenced:

CLSI EP09-A3: Measurement Procedure Comparison and Bias Estimation Using Patient Samples; Approved Guideline-Third Edition.   
CLSI EP06-A: Evaluation of the Linearity of Quantitative Measurement Procedures: A Statistical Approach.   
CLSI EP05-A3: Evaluation of Precision of Quantitative Measurement Procedures: Approved Guidelines-Third Edition.   
CLSI EP28-A3c: Defining, Establishing, and Verifying Reference Intervals in the Clinical Laboratory, 3rd Edition.   
CLSI EP07:Ed3: Interference Testing in Clinical Chemistry; Approved Guideline —Third Edition.

# VII Performance Characteristics (if/when applicable):

# A Analytical Performance:

# 1. Precision/Reproducibility:

Precision was evaluated in studies following recommendations in CLSI EP05-A3. Samples were assayed in duplicate in 2 runs per day for 20 days using 2 reagent lots on 2 ADVIA Centaur XP systems. The following results are representative of the performance of the assay:

<table><tr><td rowspan=1 colspan=3>cYanmaGellow</td><td rowspan=1 colspan=1>Repeatability</td><td rowspan=1 colspan=1>ity</td><td rowspan=1 colspan=2>Between-Run</td><td rowspan=1 colspan=2>Between-Day</td><td rowspan=1 colspan=2>Within-Lab</td></tr><tr><td rowspan=1 colspan=1>Sample TypeN</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>MeanmIU/mL(IU/L)</td><td rowspan=1 colspan=1>SDmIU/mL(IU/L)</td><td rowspan=1 colspan=1>CV (%)</td><td rowspan=1 colspan=1>SDmIU/mL(IU/L)</td><td rowspan=1 colspan=1>CV(%)</td><td rowspan=1 colspan=1>SDmIU/mL(IU/L)</td><td rowspan=1 colspan=1>CV(%)</td><td rowspan=1 colspan=1>SDmIU/mL(IU/L)</td><td rowspan=1 colspan=1>CV(%)</td></tr><tr><td rowspan=1 colspan=1>Serum A</td><td rowspan=1 colspan=1>320</td><td rowspan=1 colspan=1>6.63</td><td rowspan=1 colspan=1>0.29</td><td rowspan=1 colspan=1>4.4%</td><td rowspan=1 colspan=1>0.09</td><td rowspan=1 colspan=1>1.3%</td><td rowspan=1 colspan=1>0.24</td><td rowspan=1 colspan=1>3.6%</td><td rowspan=1 colspan=1>0.39</td><td rowspan=1 colspan=1>5.8%</td></tr><tr><td rowspan=1 colspan=1>Serum B</td><td rowspan=1 colspan=1>320</td><td rowspan=1 colspan=1>15.85</td><td rowspan=1 colspan=1>0.53</td><td rowspan=1 colspan=1>3.3%</td><td rowspan=1 colspan=1>0.45</td><td rowspan=1 colspan=1>2.8%</td><td rowspan=1 colspan=1>0.31</td><td rowspan=1 colspan=1>2.0%</td><td rowspan=1 colspan=1>0.76</td><td rowspan=1 colspan=1>4.8%</td></tr><tr><td rowspan=1 colspan=1>Serum C</td><td rowspan=1 colspan=1>320</td><td rowspan=1 colspan=1>819.28</td><td rowspan=1 colspan=1>20.25</td><td rowspan=1 colspan=1>2.5%</td><td rowspan=1 colspan=1>22.47</td><td rowspan=1 colspan=1>2.7%</td><td rowspan=1 colspan=1>12.09</td><td rowspan=1 colspan=1>1.5%</td><td rowspan=1 colspan=1>32.58</td><td rowspan=1 colspan=1>4.0%</td></tr><tr><td rowspan=1 colspan=1>Control 1</td><td rowspan=1 colspan=1>320</td><td rowspan=1 colspan=1>7.43</td><td rowspan=1 colspan=1>0.30</td><td rowspan=1 colspan=1>4.1%</td><td rowspan=1 colspan=1>0.15</td><td rowspan=1 colspan=1>2.0%</td><td rowspan=1 colspan=1>0.32</td><td rowspan=1 colspan=1>4.3%</td><td rowspan=1 colspan=1>0.46</td><td rowspan=1 colspan=1>6.2%</td></tr><tr><td rowspan=1 colspan=1>Control 2</td><td rowspan=1 colspan=1>320</td><td rowspan=1 colspan=1>24.64</td><td rowspan=1 colspan=1>0.61</td><td rowspan=1 colspan=1>2.5%</td><td rowspan=1 colspan=1>0.14</td><td rowspan=1 colspan=1>0.6%</td><td rowspan=1 colspan=1>0.58</td><td rowspan=1 colspan=1>2.3%</td><td rowspan=1 colspan=1>0.85</td><td rowspan=1 colspan=1>3.5%</td></tr><tr><td rowspan=1 colspan=1>Control 3</td><td rowspan=1 colspan=1>320</td><td rowspan=1 colspan=1>164.66</td><td rowspan=1 colspan=1>2.96</td><td rowspan=1 colspan=1>1.8%</td><td rowspan=1 colspan=1>0.79</td><td rowspan=1 colspan=1>0.5%</td><td rowspan=1 colspan=1>2.71</td><td rowspan=1 colspan=1>1.6%</td><td rowspan=1 colspan=1>4.09</td><td rowspan=1 colspan=1>2.5%</td></tr></table>

2. Linearity:

Linearity of the ADVIA Centaur $\textsuperscript { \textregistered }$ Total hCG assay was performed following recommendations in CLSI EP06- A guideline. Thirteen (13) samples were prepared by serially diluting a high hCG concentration sample with a low concentration serum sample. The study was performed using one (1) reagent lot and three replicates per level on one ADVIA Centaur XP system. Linearity was evaluated using weighted linear regression. The linearity study included samples spanning hCG concentrations from 1.7 to $1 1 2 6 \mathrm { m I U / m L }$ .

The expected and recovered hCG were plotted and gave the following linear regression equation:

$$
O b s e r \nu e d = 0 . 9 9 ( E x p e c t e d ) + 0 . 1 2 m I U / m L
$$

The results from the linearity study support an analytical measuring range from 4.0 mIU/mL to $1 0 0 0 \mathrm { m I U / m L }$ .

# Dilution Recovery

The sponsor provided dilution studies which supported the measurement of samples above $1 0 0 0 \mathrm { m I U / m L }$ for samples diluted by a factor of 2, 4, 8 or 16.

3. Analytical Specificity/Interference:

# Interferences

Interference testing was conducted following recommendations in CLSI EP07 guideline. To test the interferents listed below, two (2) female human serum pools were prepared by spiking a female serum sample pool with a high concentration hCG serum sample pool from a pregnant female to create a low (around $5 . 0 \mathrm { m I U / m L }$ ) and a high (around $5 0 0 \mathrm { m I U / m L }$ ) concentration level sample pool. These base pools were divided further into two parts for each interferent; a control sample with no interferent present (spiked with interferent vehicle only) and a spiked sample with interferent present. The interferents were tested at multiple concentrations as presented below including a low and/or mid and/or a high-level concentration. Testing was done with two (2) ADVIA Centaur ThCG reagent lots on one (1) ADVIA Centaur XP system with four (4) replicates.

The observed interference effect, Dobs, was computed as the difference between the means of the test and control samples.

Dobs $=$ Interference $=$ (test sample mean – control sample mean)

To report the level of interferent for a quantitative assay as percent $( \% )$ bias, the following   
calculation was used:   
$\%$ Bias $= [ 1 0 0 ^ { * }$ Dobs ] / [control sample mean]

There was no significant interference (defined by the sponsor as $\leq 1 0 \%$ bias) up to the concentrations summarized below:

<table><tr><td rowspan=1 colspan=1>Substance</td><td rowspan=1 colspan=1>Highest Substance Concentrationtested at which no significantinterference was observed</td></tr><tr><td rowspan=1 colspan=1>Human Serum Albumin</td><td rowspan=1 colspan=1>6 g/dL</td></tr><tr><td rowspan=1 colspan=1>Acetaminophen</td><td rowspan=1 colspan=1>20 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Acetylsalicylic acid</td><td rowspan=1 colspan=1>65 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Heparin</td><td rowspan=1 colspan=1>7200 IU/dL</td></tr><tr><td rowspan=1 colspan=1>Ibuprofen</td><td rowspan=1 colspan=1>50 mg/dL</td></tr><tr><td rowspan=1 colspan=1>EDTA</td><td rowspan=1 colspan=1>3.4 μmol/L</td></tr><tr><td rowspan=1 colspan=1>Ethanol</td><td rowspan=1 colspan=1>600 mg /dL</td></tr><tr><td rowspan=1 colspan=1>Atropine</td><td rowspan=1 colspan=1>20 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Caffeine</td><td rowspan=1 colspan=1>556 um/L</td></tr><tr><td rowspan=1 colspan=1>Gentisic acid</td><td rowspan=1 colspan=1>117 µmol/L</td></tr><tr><td rowspan=1 colspan=1>Bilirubin (Conjugated)</td><td rowspan=1 colspan=1>40 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Bilirubin (Unconjugated)</td><td rowspan=1 colspan=1>40 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Hemoglobin</td><td rowspan=1 colspan=1>1000 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Intralipid</td><td rowspan=1 colspan=1>3000 mg/dL</td></tr></table>

# Cross-Reactivity

Cross-reactivity testing was performed using two (2) ADVIA Centaur $\textsuperscript { \textregistered }$ ThCG reagent lots on one (1) ADVIA Centaur XP system at four hCG concentrations around: 0, 10, 50 and 500 $\mathrm { m U / m L }$ . Measurements were made in four replicates per sample. The cross-reactants were tested at the concentrations listed in the table below.

<table><tr><td rowspan=1 colspan=1>Cross-Reactant</td><td rowspan=1 colspan=1>hCG ResultControl Sample(mIU/mL)</td><td rowspan=1 colspan=1>hCG ResultSpiked Sample(mIU/mL)</td><td rowspan=1 colspan=1>% Change</td></tr><tr><td rowspan=3 colspan=1>FSH500 mIU/mL</td><td rowspan=1 colspan=1>7.7</td><td rowspan=1 colspan=1>8.0</td><td rowspan=1 colspan=1>4%</td></tr><tr><td rowspan=1 colspan=1>54.9</td><td rowspan=1 colspan=1>54.4</td><td rowspan=1 colspan=1>-1%</td></tr><tr><td rowspan=1 colspan=1>493.1</td><td rowspan=1 colspan=1>475.4</td><td rowspan=1 colspan=1>-4%</td></tr><tr><td rowspan=3 colspan=1>TSH1000 μIU/mL</td><td rowspan=1 colspan=1>7.6</td><td rowspan=1 colspan=1>7.4</td><td rowspan=1 colspan=1>-3%</td></tr><tr><td rowspan=1 colspan=1>54.2</td><td rowspan=1 colspan=1>51.6</td><td rowspan=1 colspan=1>-5%</td></tr><tr><td rowspan=1 colspan=1>499.9</td><td rowspan=1 colspan=1>462.9</td><td rowspan=1 colspan=1>-7%</td></tr><tr><td rowspan=3 colspan=1>LH500 mIU/mL</td><td rowspan=1 colspan=1>7.8</td><td rowspan=1 colspan=1>7.0</td><td rowspan=1 colspan=1>-10%</td></tr><tr><td rowspan=1 colspan=1>56.2</td><td rowspan=1 colspan=1>47.7</td><td rowspan=1 colspan=1>-15%</td></tr><tr><td rowspan=1 colspan=1>487.9</td><td rowspan=1 colspan=1>428.5</td><td rowspan=1 colspan=1>-12%</td></tr><tr><td rowspan=3 colspan=1>hGH500 ng/mL</td><td rowspan=1 colspan=1>7.3</td><td rowspan=1 colspan=1>7.2</td><td rowspan=1 colspan=1>-2%</td></tr><tr><td rowspan=1 colspan=1>53.0</td><td rowspan=1 colspan=1>52.9</td><td rowspan=1 colspan=1>0%</td></tr><tr><td rowspan=1 colspan=1>482.3</td><td rowspan=1 colspan=1>487.7</td><td rowspan=1 colspan=1>1%</td></tr><tr><td rowspan=3 colspan=1>PRL1000 ng/mL</td><td rowspan=1 colspan=1>7.9</td><td rowspan=1 colspan=1>7.5</td><td rowspan=1 colspan=1>-5%</td></tr><tr><td rowspan=1 colspan=1>54.6</td><td rowspan=1 colspan=1>54.6</td><td rowspan=1 colspan=1>0%</td></tr><tr><td rowspan=1 colspan=1>490.5</td><td rowspan=1 colspan=1>494.2</td><td rowspan=1 colspan=1>1%</td></tr></table>

# Hook Effect

No high dose hook effect was observed up to $5 0 0 , 0 0 0 \mathrm { m I U / m L }$ .

4. Assay Reportable Range: The assay analytical measuring interval ranges from $4 . 0 \ : \mathrm { m I U / m L }$ to 1000 mIU/mL.

5. Traceability, Stability, Expected Values (Controls, Calibrators, or Methods):

# Traceability

The ADVIA Centaur Total hCG assay is traceable to the World Health Organization WHO 5th IS 7/364 reference material.

# 6. Detection Limit:

The limit of blank (LoB), limit of detection (LoD) and limit of quantitation (LoQ) were evaluated to determine detection capabilities using the ADVIA Centaur $\textsuperscript { \textregistered }$ XP System according to internal procedure governed by CLSI guideline EP17-A2.

# Limit of Blank

LoB testing was performed using two (2) reagent lots on one (1) ADVIA Centaur XP instrument. The study consisted of four (4) blank samples (various diluent pools with no detectable level of hCG) that were tested in 5 replicates per sample, 2 runs per day, and 5 test days for a total of 200 replicates per reagent lot. Results were calculated using two-point calibration stored from first day of testing. The maximum observed LoB across all reagent lots was $1 . 1 4 ~ \mathrm { m I U / m L }$ .

# Limit of Detection

LoD testing was performed using two (2) reagent lots on one (1) ADVIA Centaur $\textsuperscript { \textregistered }$ XP instrument. The study consisted of 10 samples that were tested in 5 replicates per sample per run, 2 runs per day, and 5 test days. Results were calculated using two-point calibration stored from first day of testing.

For each reagent lot, LoD was determined using 694 determinations and an LoB of 1.14 $\mathrm { m U / m L }$ . Using the precision profile protocol, the LoD was determined as the dose at which $9 5 \%$ of the measurements would be greater than the LoB. The highest LoB was used in the calculations of the LoD. The maximum observed LoD across all reagent lots was 1.99 mIU/mL.

LoQ was determined by testing six human low concentration serum sample pools in the hCG concentration range of $1 . 4 - 8 . 2 \mathrm { m I U / m L }$ . Testing was performed on two (2) ADVIA Centaur $\textsuperscript { \textregistered }$ reagents lots on one ADVIA Centaur XP system. Each sample was tested in five (5) replicates for ten (10) runs over a period of five (5) days, yielding a total of 300 determinations for each reagent lot. The largest LoQ observed result across all reagent lots tested was $3 . 9 \mathrm { \ m I U / m L }$ and the sponsor claimed LoQ is $4 . 0 \ : \mathrm { m I U / m L }$ . The LoQ study incorporated both precision and a bias component with a $30 \%$ error limit.

<table><tr><td rowspan=1 colspan=1>Detection Capabilities</td><td rowspan=1 colspan=1>mIU/mL</td></tr><tr><td rowspan=1 colspan=1>LoQ</td><td rowspan=1 colspan=1>4.0</td></tr><tr><td rowspan=1 colspan=1>LoD</td><td rowspan=1 colspan=1>3.0</td></tr><tr><td rowspan=1 colspan=1>LoB</td><td rowspan=1 colspan=1>2.0</td></tr></table>

7. Assay Cut-Off:

Not applicable

# B Comparison Studies:

1. Method Comparison with Predicate Device:

Method comparison studies were conducted following recommendations in CLSI EP09-A3 guideline. Serum samples were measured in singlicate using one (1) ADVIA Centaur Total hCG reagent lot on one (1) ADVIA Centaur XP system (candidate device) and one (1) Atellica IM ThCG reagent lot on one (1) Atellica IM analyzer (predicate device). A total of 117 serum samples including 12 contrived serum samples were evaluated. The following results were obtained:

$\mathrm { y } = 0 . 9 6 \mathrm { x } - 3 . 0 \mathrm { m I U } / \mathrm { m L }$ , Correlation coefficient $\mathbf { \rho } ( \mathbf { r } ) = 0 . 9 9 7$

# 2. Matrix Comparison:

Serum and plasma (K2 EDTA and lithium heparin) sample equivalence was evaluated by matrix comparison studies by testing matched-sample sets spanning the measurement range of the assay. The studies were conducted following recommendations in CLSI EP09-A3 guideline. The following results were obtained.

<table><tr><td rowspan=1 colspan=1>Tube (y) vs. Serum (x)</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>Sample Interval</td><td rowspan=1 colspan=1>Slope</td><td rowspan=1 colspan=1>Intercept</td><td rowspan=1 colspan=1>r</td></tr><tr><td rowspan=1 colspan=1>Dipotassium EDTAplasma</td><td rowspan=1 colspan=1>53</td><td rowspan=1 colspan=1>4.7 - 948.9 mIU/mL</td><td rowspan=1 colspan=1>0.99</td><td rowspan=1 colspan=1>0.3</td><td rowspan=1 colspan=1>1.00</td></tr><tr><td rowspan=1 colspan=1>Lithium heparin plasma</td><td rowspan=1 colspan=1>51</td><td rowspan=1 colspan=1>4.7 - 975.7 mIU/mL</td><td rowspan=1 colspan=1>1.01</td><td rowspan=1 colspan=1>- 0.3</td><td rowspan=1 colspan=1>1.00</td></tr></table>

# C Clinical Studies:

1. Clinical Sensitivity: Not applicable

2. Clinical Specificity: Not applicable

3. Other Clinical Supportive Data (When 1. and 2. Are Not Applicable): Not applicable

# D Clinical Cut-Off:

Not applicable

# E Expected Values/Reference Range:

The reference range study was performed following recommendations in CLSI EP28-A3c guideline. The following results were obtained:

<table><tr><td rowspan=1 colspan=1>Sample Category</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>Median (mIU/mL)(I∪/L)</td><td rowspan=1 colspan=1>Reference IntervalmIU/mL)(IU/L)2.5-97.5 Percentile</td></tr><tr><td rowspan=1 colspan=1>Non-Pregnant Females(Age: ≤40)</td><td rowspan=1 colspan=1>130</td><td rowspan=1 colspan=1>0.03</td><td rowspan=1 colspan=1>0.03 - 0.6</td></tr><tr><td rowspan=1 colspan=1>Post-menopausalFemales(Age: ≥41)</td><td rowspan=1 colspan=1>150</td><td rowspan=1 colspan=1>0.02</td><td rowspan=1 colspan=1>0.02 - 2.9</td></tr></table>

# VIII Proposed Labeling:

The labeling supports the finding of substantial equivalence for this device.

# IX Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.